Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73


Mating skew in Barbary macaque males: the role of female mating synchrony, female behavior, and male-male coalitions.

Bissonnette A, Bischofberger N, van Schaik CP.

Behav Ecol Sociobiol. 2011 Feb;65(2):167-182. Epub 2010 Jul 23.


Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.

Van Rompay KK, Durand-Gasselin L, Brignolo LL, Ray AS, Abel K, Cihlar T, Spinner A, Jerome C, Moore J, Kearney BP, Marthas ML, Reiser H, Bischofberger N.

Antimicrob Agents Chemother. 2008 Sep;52(9):3144-60. doi: 10.1128/AAC.00350-08. Epub 2008 Jun 23.


Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy.

Ambrose Z, Palmer S, Boltz VF, Kearney M, Larsen K, Polacino P, Flanary L, Oswald K, Piatak M Jr, Smedley J, Shao W, Bischofberger N, Maldarelli F, Kimata JT, Mellors JW, Hu SL, Coffin JM, Lifson JD, KewalRamani VN.

J Virol. 2007 Nov;81(22):12145-55. Epub 2007 Sep 12.


The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.

Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, Clotet B, Lazzarin A, Schewe K, Lange J, Wyatt C, Curtis S, Chen SS, Smith S, Bischofberger N, Rooney JF.

AIDS. 2007 Jun 19;21(10):1273-81.


Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.

Van Rompay KK, Johnson JA, Blackwood EJ, Singh RP, Lipscomb J, Matthews TB, Marthas ML, Pedersen NC, Bischofberger N, Heneine W, North TW.

Retrovirology. 2007 Apr 6;4:25.


Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization.

von Gegerfelt AS, Rosati M, Alicea C, Valentin A, Roth P, Bear J, Franchini G, Albert PS, Bischofberger N, Boyer JD, Weiner DB, Markham P, Israel ZR, Eldridge JH, Pavlakis GN, Felber BK.

J Virol. 2007 Feb;81(4):1972-9. Epub 2006 Nov 29.


Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus.

Van Rompay KK, Kearney BP, Sexton JJ, Colón R, Lawson JR, Blackwood EJ, Lee WA, Bischofberger N, Marthas ML.

J Acquir Immune Defic Syndr. 2006 Sep;43(1):6-14.


Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques.

Van Rompay KK, Singh RP, Heneine W, Johnson JA, Montefiori DC, Bischofberger N, Marthas ML.

J Virol. 2006 Jul;80(13):6399-410.


Magnetic resonance spectroscopy reveals that activated monocytes contribute to neuronal injury in SIV neuroAIDS.

Williams K, Westmoreland S, Greco J, Ratai E, Lentz M, Kim WK, Fuller RA, Kim JP, Autissier P, Sehgal PK, Schinazi RF, Bischofberger N, Piatak M, Lifson JD, Masliah E, González RG.

J Clin Invest. 2005 Sep;115(9):2534-45. Epub 2005 Aug 18.


Pharmacokinetics of tenofovir in breast milk of lactating rhesus macaques.

Van Rompay KK, Hamilton M, Kearney B, Bischofberger N.

Antimicrob Agents Chemother. 2005 May;49(5):2093-4.


Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptor.

Cattaneo M, Lecchi A, Ohno M, Joshi BV, Besada P, Tchilibon S, Lombardi R, Bischofberger N, Harden TK, Jacobson KA.

Biochem Pharmacol. 2004 Nov 15;68(10):1995-2002.


Tenofovir primes rhesus macaque cells in vitro for enhanced interleukin-12 secretion.

Van Rompay KK, Marthas ML, Bischofberger N.

Antiviral Res. 2004 Aug;63(2):133-8.


The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters.

Van Rompay KK, Singh RP, Brignolo LL, Lawson JR, Schmidt KA, Pahar B, Canfield DR, Tarara RP, Sodora DL, Bischofberger N, Marthas ML.

J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):900-14.


CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment.

Van Rompay KK, Singh RP, Pahar B, Sodora DL, Wingfield C, Lawson JR, Marthas ML, Bischofberger N.

J Virol. 2004 May;78(10):5324-37.


Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques.

Van Rompay KK, Brignolo LL, Meyer DJ, Jerome C, Tarara R, Spinner A, Hamilton M, Hirst LL, Bennett DR, Canfield DR, Dearman TG, Von Morgenland W, Allen PC, Valverde C, Castillo AB, Martin RB, Samii VF, Bendele R, Desjardins J, Marthas ML, Pedersen NC, Bischofberger N.

Antimicrob Agents Chemother. 2004 May;48(5):1469-87. Erratum in: Antimicrob Agents Chemother. 2994 Jan;48(6):2346.


Acyclic analogues of adenosine bisphosphates as P2Y receptor antagonists: phosphate substitution leads to multiple pathways of inhibition of platelet aggregation.

Xu B, Stephens A, Kirschenheuter G, Greslin AF, Cheng X, Sennelo J, Cattaneo M, Zighetti ML, Chen A, Kim SA, Kim HS, Bischofberger N, Cook G, Jacobson KA.

J Med Chem. 2002 Dec 19;45(26):5694-709.


Topical administration of low-dose tenofovir disoproxil fumarate to protect infant macaques against multiple oral exposures of low doses of simian immunodeficiency virus.

Van Rompay KK, Schmidt KA, Lawson JR, Singh R, Bischofberger N, Marthas ML.

J Infect Dis. 2002 Nov 15;186(10):1508-13. Epub 2002 Oct 29.


Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta).

Tarantal AF, Castillo A, Ekert JE, Bischofberger N, Martin RB.

J Acquir Immune Defic Syndr. 2002 Mar 1;29(3):207-20.


Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment.

Lifson JD, Rossio JL, Piatak M Jr, Parks T, Li L, Kiser R, Coalter V, Fisher B, Flynn BM, Czajak S, Hirsch VM, Reimann KA, Schmitz JE, Ghrayeb J, Bischofberger N, Nowak MA, Desrosiers RC, Wodarz D.

J Virol. 2001 Nov;75(21):10187-99.


Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection.

Van Rompay KK, McChesney MB, Aguirre NL, Schmidt KA, Bischofberger N, Marthas ML.

J Infect Dis. 2001 Aug 15;184(4):429-38. Epub 2001 Jul 16.


Enhanced cellular immune response and reduced CD8(+) lymphocyte apoptosis in acutely SIV-infected Rhesus macaques after short-term antiretroviral treatment.

Spring M, Stahl-Hennig C, Stolte N, Bischofberger N, Heeney J, ten Haaft P, Tenner-Ràcz K, Ràcz P, Lorenzen D, Hunsmann G, Dittmer U.

Virology. 2001 Jan 5;279(1):221-32.


Development of virus-specific immune responses in SHIV(KU)-infected macaques treated with PMPA.

Kumar A, Buch S, Foresman L, Bischofberger N, Lifson JD, Narayan O.

Virology. 2001 Jan 5;279(1):97-108.


Post-exposure chemoprophylaxis (PECP) against SIV infection of macaques as a model for protection from HIV infection.

Tsai CC, Emau P, Sun JC, Beck TW, Tran CA, Follis KE, Bischofberger N, Morton WR.

J Med Primatol. 2000 Aug;29(3-4):248-58.


Lasting effects of transient postinoculation tenofovir [9-R-(2-Phosphonomethoxypropyl)adenine] treatment on SHIV(KU2) infection of rhesus macaques.

Smith MS, Foresman L, Lopez GJ, Tsay J, Wodarz D, Lifson JD, Page A, Wang C, Li Z, Adany I, Buch S, Bischofberger N, Narayan O.

Virology. 2000 Nov 25;277(2):306-15.


Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques.

Hel Z, Venzon D, Poudyal M, Tsai WP, Giuliani L, Woodward R, Chougnet C, Shearer G, Altman JD, Watkins D, Bischofberger N, Abimiku A, Markham P, Tartaglia J, Franchini G.

Nat Med. 2000 Oct;6(10):1140-6.


Antiviral treatment normalizes neurophysiological but not movement abnormalities in simian immunodeficiency virus-infected monkeys.

Fox HS, Weed MR, Huitron-Resendiz S, Baig J, Horn TF, Dailey PJ, Bischofberger N, Henriksen SJ.

J Clin Invest. 2000 Jul;106(1):37-45.


Effect of PMPA and PMEA on the kinetics of viral load in simian immunodeficiency virus-infected macaques.

Silvera P, Racz P, Racz K, Bischofberger N, Crabbs C, Yalley-Ogunro J, Greenhouse J, Jiang JB, Lewis MG.

AIDS Res Hum Retroviruses. 2000 May 20;16(8):791-800.


The origin and control of pandemic influenza.

Laver WG, Bischofberger N, Webster RG.

Perspect Biol Med. 2000 Winter;43(2):173-92. No abstract available.


Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment.

Lifson JD, Rossio JL, Arnaout R, Li L, Parks TL, Schneider DK, Kiser RF, Coalter VJ, Walsh G, Imming RJ, Fisher B, Flynn BM, Bischofberger N, Piatak M Jr, Hirsch VM, Nowak MA, Wodarz D.

J Virol. 2000 Mar;74(6):2584-93.


Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.

Van Rompay KK, Miller MD, Marthas ML, Margot NA, Dailey PJ, Canfield DR, Tarara RP, Cherrington JM, Aguirre NL, Bischofberger N, Pedersen NC.

J Virol. 2000 Feb;74(4):1767-74.


Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques.

Rosenwirth B, ten Haaft P, Bogers WM, Nieuwenhuis IG, Niphuis H, Kuhn EM, Bischofberger N, Heeney JL, Uberla K.

J Virol. 2000 Feb;74(4):1704-11.


An anti-HIV strategy combining chemotherapy and therapeutic vaccination.

Rosenwirth B, Bogers WM, Nieuwenhuis IG, Haaft PT, Niphuis H, Kuhn EM, Bischofberger N, Erfle V, Sutter G, Berglund P, Liljestrom P, Uberla K, Heeney JL.

J Med Primatol. 1999 Aug-Oct;28(4-5):195-205.


Postinoculation PMPA treatment, but not preinoculation immunomodulatory therapy, protects against development of acute disease induced by the unique simian immunodeficiency virus SIVsmmPBj.

Hodge S, de Rosayro J, Glenn A, Ojukwu IC, Dewhurst S, McClure HM, Bischofberger N, Anderson DC, Klumpp SA, Novembre FJ.

J Virol. 1999 Oct;73(10):8630-9.


Protection against ischemic damage by adenosine amine congener, a potent and selective adenosine A1 receptor agonist.

Von Lubitz DK, Lin RC, Bischofberger N, Beenhakker M, Boyd M, Lipartowska R, Jacobson KA.

Eur J Pharmacol. 1999 Mar 26;369(3):313-7.


9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA.

Van Rompay KK, Cherrington JM, Marthas ML, Lamy PD, Dailey PJ, Canfield DR, Tarara RP, Bischofberger N, Pedersen NC.

Antimicrob Agents Chemother. 1999 Apr;43(4):802-12.


Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies.

Tarantal AF, Marthas ML, Shaw JP, Cundy K, Bischofberger N.

J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Apr 1;20(4):323-33.


Chronic administration of adenosine A3 receptor agonist and cerebral ischemia: neuronal and glial effects.

Von Lubitz DK, Lin RC, Boyd M, Bischofberger N, Jacobson KA.

Eur J Pharmacol. 1999 Feb 19;367(2-3):157-63.


Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaques.

van Rompay KK, Dailey PJ, Tarara RP, Canfield DR, Aguirre NL, Cherrington JM, Lamy PD, Bischofberger N, Pedersen NC, Marthas ML.

J Virol. 1999 Apr;73(4):2947-55.


Disarming flu viruses.

Laver WG, Bischofberger N, Webster RG.

Sci Am. 1999 Jan;280(1):78-87. No abstract available.


In vitro and in vivo activities of oligodeoxynucleotide-based thrombin inhibitors containing neutral formacetal linkages.

He GX, Williams JP, Postich MJ, Swaminathan S, Shea RG, Terhorst T, Law VS, Mao CT, Sueoka C, Coutré S, Bischofberger N.

J Med Chem. 1998 Oct 22;41(22):4224-31.


Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection.

Van Rompay KK, Berardi CJ, Aguirre NL, Bischofberger N, Lietman PS, Pedersen NC, Marthas ML.

AIDS. 1998 Jun 18;12(9):F79-83.


Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice.

Naesens L, Bischofberger N, Augustijns P, Annaert P, Van den Mooter G, Arimilli MN, Kim CU, De Clercq E.

Antimicrob Agents Chemother. 1998 Jul;42(7):1568-73.


Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques.

Van Rompay KK, Marthas ML, Lifson JD, Berardi CJ, Vasquez GM, Agatep E, Dehqanzada ZA, Cundy KC, Bischofberger N, Pedersen NC.

AIDS Res Hum Retroviruses. 1998 Jun 10;14(9):761-73.


N2- and C8-substituted oligodeoxynucleotides with enhanced thrombin inhibitory activity in vitro and in vivo.

He GX, Krawczyk SH, Swaminathan S, Shea RG, Dougherty JP, Terhorst T, Law VS, Griffin LC, Coutré S, Bischofberger N.

J Med Chem. 1998 Jun 18;41(13):2234-42.


Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071.

Li W, Escarpe PA, Eisenberg EJ, Cundy KC, Sweet C, Jakeman KJ, Merson J, Lew W, Williams M, Zhang L, Kim CU, Bischofberger N, Chen MS, Mendel DB.

Antimicrob Agents Chemother. 1998 Mar;42(3):647-53.


Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection.

Mendel DB, Tai CY, Escarpe PA, Li W, Sidwell RW, Huffman JH, Sweet C, Jakeman KJ, Merson J, Lacy SA, Lew W, Williams MA, Zhang L, Chen MS, Bischofberger N, Kim CU.

Antimicrob Agents Chemother. 1998 Mar;42(3):640-6.

Supplemental Content

Loading ...
Support Center